Best Treatments for SAPHO Syndrome
For SAPHO syndrome, start with NSAIDs as first-line therapy, escalate to intravenous bisphosphonates as second-line treatment, and reserve TNF-α inhibitors or JAK inhibitors for refractory cases, with treatment choice guided by the presence of additional inflammatory features.
Treatment Algorithm
First-Line Treatment
Begin with NSAIDs or COX-2 inhibitors for all patients with active disease 1. This addresses the inflammatory bone pain that characterizes SAPHO syndrome and should be trialed for adequate duration before escalation.
Second-Line Treatment
When NSAIDs fail or provide insufficient control, the 2025 EULAR expert consensus recommends intravenous bisphosphonates as the preferred second-line option 1. Bisphosphonates directly target the abnormal bone metabolism and hyperostosis that define SAPHO syndrome 2.
TNF-α inhibitors represent an alternative second-line choice, particularly when:
- Prominent inflammatory arthritis is present
- Significant dermatological manifestations coexist
- Bisphosphonates are contraindicated or poorly tolerated
The choice between bisphosphonates and TNF-α inhibitors should be individualized based on the patient's inflammatory phenotype 1.
Third-Line and Refractory Disease
For patients failing conventional second-line therapies, JAK inhibitors have emerged as highly effective options with a 98.6% response rate across 72 reported cases 3. Specifically:
- Tofacitinib (most extensively studied, used in 75% of reported cases)
- Baricitinib (20.8% of cases)
- Upadacitinib (4.2% of cases, but showing rapid symptom resolution) 4, 3
JAK inhibitors demonstrate particular efficacy when IL-17 inhibitors fail, as illustrated by successful upadacitinib use after secukinumab failure 4.
Additional Therapeutic Considerations
Conventional DMARDs (methotrexate, sulfasalazine) can be considered for managing disease progression, particularly when prominent synovitis is present 2.
Antibiotics and tonsillectomy may address focal infections that trigger immune dysregulation in select cases, though this remains controversial 2.
IL-23 inhibitors (guselkumab) combined with JAK inhibitors represent an emerging option for truly refractory cases, with one 2026 report showing complete pain resolution within 2 weeks 5.
Key Clinical Pitfalls
- Don't delay escalation: Untreated SAPHO leads to skeletal deformities, joint ankylosis, and vertebral fractures 1
- Monitor for paradoxical reactions: Biological agents can occasionally worsen cutaneous manifestations
- JAK inhibitor adverse effects: While generally manageable (13.9% adverse effect rate), monitor for infections and cytopenias 3
- Recognize the spectrum: SAPHO is now termed "chronic non-bacterial osteitis (CNO)" in adults, reflecting the broader disease spectrum 1
Diagnostic Imaging Before Treatment
Obtain MRI as first-line imaging or CT combined with nuclear imaging if MRI unavailable. Consider whole-body imaging initially for diagnostic and prognostic purposes 1. This identifies the extent of bone involvement and guides treatment intensity.
The evidence strongly supports this stepwise approach, with the 2025 EULAR guidelines 1 providing the framework and recent JAK inhibitor data 3 offering new options for refractory disease. The high response rates with JAK inhibitors (98.6%) suggest they may eventually move earlier in the treatment algorithm as more safety data accumulates.